Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UpFrontPSMA: 177Lu-PSMA617 and Docetaxel in Metastatic Hormone-Naive Prostate Cancer
NCT04343885Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Apr 2020
- Primary completion
- Mar 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Peter MacCallum Cancer Centre. Started Apr 2020; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04343885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04343885.